Sanofi has acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofi’s research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones.
Read the full article: Sanofi Acquires Tidal Therapeutics //
Source: https://www.globenewswire.com/news-release/2021/04/09/2207664/0/en/Sanofi-acquires-Tidal-Therapeutics-adding-innovative-mRNA-based-research-platform-with-applications-in-oncology-immunology-and-other-disease-areas.html